GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (TSX:EPRX) » Definitions » Enterprise Value

Eupraxia Pharmaceuticals (TSX:EPRX) Enterprise Value : C$94.11 Mil (As of Jun. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Eupraxia Pharmaceuticals Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Eupraxia Pharmaceuticals's Enterprise Value is C$94.11 Mil. Eupraxia Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was C$-35.61 Mil. Therefore, Eupraxia Pharmaceuticals's EV-to-EBIT ratio for today is -2.64.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Eupraxia Pharmaceuticals's Enterprise Value is C$94.11 Mil. Eupraxia Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was C$-35.40 Mil. Therefore, Eupraxia Pharmaceuticals's EV-to-EBITDA ratio for today is -2.66.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Eupraxia Pharmaceuticals's Enterprise Value is C$94.11 Mil. Eupraxia Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.00 Mil. Therefore, Eupraxia Pharmaceuticals's EV-to-Revenue ratio for today is .


Eupraxia Pharmaceuticals Enterprise Value Historical Data

The historical data trend for Eupraxia Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eupraxia Pharmaceuticals Enterprise Value Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial - - 13.63 65.43 132.80

Eupraxia Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 91.98 196.09 168.43 132.80 113.78

Competitive Comparison of Eupraxia Pharmaceuticals's Enterprise Value

For the Biotechnology subindustry, Eupraxia Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eupraxia Pharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Eupraxia Pharmaceuticals's Enterprise Value falls into.



Eupraxia Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Eupraxia Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Eupraxia Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eupraxia Pharmaceuticals  (TSX:EPRX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Eupraxia Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=94.108/-35.611
=-2.64

Eupraxia Pharmaceuticals's current Enterprise Value is C$94.11 Mil.
Eupraxia Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-35.61 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Eupraxia Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=94.108/-35.398
=-2.66

Eupraxia Pharmaceuticals's current Enterprise Value is C$94.11 Mil.
Eupraxia Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-35.40 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Eupraxia Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=94.108/0
=

Eupraxia Pharmaceuticals's current Enterprise Value is C$94.11 Mil.
Eupraxia Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eupraxia Pharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of Eupraxia Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Eupraxia Pharmaceuticals (TSX:EPRX) Business Description

Traded in Other Exchanges
Address
201-2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms.
Executives
James Allen Helliwell Director